Sunday July 23rd 2017

Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis

Conclusions: The number of patients becoming pregnant during fingolimod therapy remains small and does not permit firm conclusions to be drawn about fetal safety of fingolimod in humans. Given the known risks of teratogenicity in animals and the present data, women of childbearing potential should use effective contraception during fingolimod therapy and for 2 months after discontinuation. (Source: Neurology)

Continue reading – 

Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis

Leave a Comment

More from category

Mothers who breastfeed might have lower multiple sclerosis risk
Mothers who breastfeed might have lower multiple sclerosis risk

(Reuters Health) - Women who breastfeed may have a lower risk of developing multiple sclerosis later in life compared [Read More]

Lipoic acid in nutritional supplements found to help prevent multiple sclerosis, study finds
Lipoic acid in nutritional supplements found to help prevent multiple sclerosis, study finds

(Natural News) The results of a new pilot study showed the efficacy of lipoic acid in the reduction of whole brain [Read More]

Multiple sclerosis symptoms: Immune system problems can trigger PARALYSIS of the legs
Multiple sclerosis symptoms: Immune system problems can trigger PARALYSIS of the legs

MULTIPLE sclerosis - commonly abbreviated to MS - is a type of autoimmune disease which can cause problems with vision, [Read More]

National Patient-Advocacy Organizations Oppose ACA Repeal
National Patient-Advocacy Organizations Oppose ACA Repeal

/About-the-Society/News/National-Patient-Advocacy-Organizations-Oppose-ACA [Read More]

Exclusive: Nurses reluctant to discuss disability with MS patients
Exclusive: Nurses reluctant to discuss disability with MS patients

Nearly two-thirds of specialist nurses are reluctant to discuss disability with patients who have multiple sclerosis, [Read More]